CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Jordan

2018-02-15
Price :
Published : Feb-2018
No. of Pages : 87

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Jordan

Summary

GlobalData, the industry analysis specialist, has released its latest report, “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Jordan”. The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Jordan. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of Jordan. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical market. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalData’s team of industry experts.

Jordan is a growing healthcare market in MENA region, with a strong focus on medical tourism. It spends approximately 10% of its GDP on healthcare. The value of the pharmaceutical market increased from $0.52 billion in 2009 to $0.91 billion in 2014, at a compound annual growth rate (CAGR) of 12%. The market is expected to reach $2 billion in 2021. The Jordanian medical device market is estimated at $243.7m in 2015 and is expected to reach $380.9m in 2018. The increasing elderly population and associated disease burden are expected to drive the growth of the pharmaceutical market.

Scope

The report provides information on the healthcare, regulatory, and reimbursement landscape in Jordan, and includes –
– An overview of the pharmaceutical market, comprising market size, segmentation, and key drivers and barriers
– Profiles and SWOT analyses of the major players in the pharmaceutical market (Hikma, Dar Al Dawa, Jordanian Pharmaceutical Manufacturing, Novartis and Merck) and medical devices market (GE Healthcare)
– Porter’s five forces analysis for pharmaceutical and medical devices market of Jordan
– An insightful review of the reimbursement and regulatory landscape, of which analysis includes details of the healthcare reimbursement process, the regulatory agencies and the approval processes for new drugs and medical devices
– Information regarding recent healthcare policies along with healthcare infrastructure and healthcare expenditure
– An overview of the opportunities for and challenges to growth in the Jordanian healthcare market.

Reasons to buy

This report will enhance your decision-making capability by allowing you to –
– Develop business strategies by understanding the trends shaping and driving the Jordanian healthcare market
– Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments, and companies likely to impact the healthcare market in the future
– Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors
– Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment, and strategic partnership
– Identify, understand, and capitalize on the opportunities and challenges in the Jordanian healthcare market.

Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
Publisher : GlobalData
More Reports
Title Price Buy Now

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – New Zealand

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - New Zealand Summary GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - New Zealand". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in New Zealand. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of New Zealand. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, a......
$1995

Partnerships, Licensing, Investments and M&A Deals and Trends for 2017 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for 2017 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for 2017 in Pharmaceuticals", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in 2017. The report portrays detailed comparative data on the number of deals and their value in the last five years, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on th......
$3500

Osteoporosis: Epidemiology Forecast to 2027

Osteoporosis: Epidemiology Forecast to 2027 Summary Osteoporosis is a disease in which the density and quality of bone are reduced over time. In a normal process known as remodeling, some of a person's bone cells dissolve (resorption) and new bone cells grow back (formation). The bones become so weak and brittle that a fall or even mild stresses such as bending over or coughing can cause a fracture. To forecast the total prevalent cases and diagnosed prevalent cases of osteoporosis and osteopenia in the 7MM, GlobalData epidemiologists selected nationally representative, population-based studies that provided these epidemiological data in the 7MM. GlobalData epidemiologists obtained data for the total prevalent cases of osteoporosis secondary to glucocorticoid use from primary market res......
$3995

PharmSource – CMO Scorecard: Outsourcing of NDA Approvals and CMO Performance – 2018 Edition

PharmSource - CMO Scorecard: Outsourcing of NDA Approvals and CMO Performance - 2018 Edition Summary This report is the 8th edition of our long running analysis of the CMO Industry, using NDA approvals as the primary indicator of performance. CMO Scorecard is critical for benchmarking the performance of the CMO industry and the relative performance of major CMOs. Reasons to buy This 43-page report gives important, expert insight you won't find in any other source. 28 tables and figures throughout the report illustrate major points and trends. This report is required reading for - - CMO executives who must have deep understanding of the injectables marketplace to make strategic planning and investment decisions. - Sourcing and procurement executives who must understand crucial componen......
$4995

Partnerships, Licensing, Investments and M&A Deals and Trends for February 2018 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for February 2018 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for February 2018 in Pharmaceuticals", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in February 2018. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report......
$1000

Transdermal Drug Delivery – Medical Devices Pipeline Assessment, 2018

Transdermal Drug Delivery - Medical Devices Pipeline Assessment, 2018 Summary GlobalData's Medical Devices sector report, "Transdermal Drug Delivery - Medical Devices Pipeline Assessment, 2018" provides an overview of Transdermal Drug Delivery currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Transdermal Drug Delivery pipeline products. This report is prepared using data sourced from in-house databases, secondary......
$4000

Auto-Immune Diseases Diagnostic Tests – Medical Devices Pipeline Assessment, 2018

Auto-Immune Diseases Diagnostic Tests - Medical Devices Pipeline Assessment, 2018 Summary GlobalData's Medical Devices sector report, "Auto-Immune Diseases Diagnostic Tests - Medical Devices Pipeline Assessment, 2018" provides an overview of Auto-Immune Diseases Diagnostic Tests currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Auto-Immune Diseases Diagnostic Tests pipeline products. This report is prepared using......
$4000

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Belgium

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Belgium Summary GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Belgium". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Belgium. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of Belgium. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house anal......
$1995

Neuromyelitis Optica (Devic’s Syndrome) Global Clinical Trials Review, H1, 2018

Neuromyelitis Optica (Devic's Syndrome) Global Clinical Trials Review, H1, 2018 Summary GlobalData's clinical trial report, "Neuromyelitis Optica (Devic's Syndrome) Global Clinical Trials Review, H1, 2018" provides an overview of Neuromyelitis Optica (Devic's Syndrome) clinical trials scenario. This report provides top line data relating to the clinical trials on Neuromyelitis Optica (Devic's Syndrome). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports ......
$2500

Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H1, 2018

Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H1, 2018 Summary GlobalData's clinical trial report, "Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H1, 2018" provides an overview of Non-Alcoholic Steatohepatitis (NASH) clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Alcoholic Steatohepatitis (NASH). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generate......
$2500